Arginase 1/ARG1/liver Arginase Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-36936
Key Product Details
Species Reactivity
Validated:
Human, Mouse, Rat, Porcine
Predicted:
Bovine (100%), Canine (100%). Backed by our 100% Guarantee.
Applications
Immunohistochemistry, Immunohistochemistry-Paraffin, Peptide ELISA, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Peptide with sequence CFGLAREGNHKPID corresponding to C-Terminus according to NP_000036.2.
Epitope
C Terminus
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Scientific Data Images for Arginase 1/ARG1/liver Arginase Antibody
Western Blot: Arginase 1/ARG1/liver Arginase Antibody [NBP1-36936]
Western Blot: Arginase 1/ARG1/liver Arginase Antibody [NBP1-36936] - Analysis of Pig (A), Mouse (B) and Rat (C) Liver lysates (35 ug protein in RIPA buffer). Antibody at 0.03 ug/mL. Primary incubation was 1 hour. Detected by chemiluminescence.Immunohistochemistry-Paraffin: Arginase 1/ARG1/liver Arginase Antibody [NBP1-36936]
Immunohistochemistry-Paraffin: Arginase 1/ARG1/liver Arginase Antibody [NBP1-36936] - Staining of paraffin embedded Human Liver. Antibody at 3.75 ug/mL. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.Western Blot: Arginase 1/ARG1/liver Arginase Antibody [NBP1-36936]
Western Blot: Arginase 1/ARG1/liver Arginase Antibody [NBP1-36936] - Staining of Human Liver lysate (35 ug protein in RIPA buffer). Antibody at 0.01 ug/mL. Detected by chemiluminescence.Applications for Arginase 1/ARG1/liver Arginase Antibody
Application
Recommended Usage
Immunohistochemistry-Paraffin
3.75 ug/mL
Peptide ELISA
Detection limit 1:64000
Western Blot
0.01 - 0.03 ug/mL
Application Notes
WB: Approx. 37 kDa band observed in human, mouse, rat and porcine liver lysates (calculated MW of 34.7 kDa band according to NP_000036.2). The observed molecular weight corresponds to earlier findings with different antibodies from other sources.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
Tris saline (20 mM Tris pH 7.3, 150 mM NaCl), 0.5% BSA
Preservative
0.02% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: Arginase 1/ARG1
Arginase and nitric oxidase synthase (NOS) compete for the same L-arginine substrate, creating a delicate balance between pathways (1). Furthermore, bioavailability of L-arginine and ARG1 expression has been implicated in several pathologies including vascular disease, neuronal disease, cardiovascular disease, immune dysfunction, inflammation, and cancer (1,3-5). For instance, ARG1 functions as a macrophage marker, defining the M2 population, while inducible nitric oxide synthase (iNOS) characterizes the M1 population; impaired M1/M2 polarization and changes in ARG1 expression is observed in diseases such as arteriogenesis, asthma, pulmonary fibrosis, and inflammatory bowel disease (1,3). In humans, arginase deficiency, known as argininemia, is an autosomal recessive metabolic disorder characterized by elevated ammonia (hyperammonemia) levels and arginine accumulation (6). Given that many arginase-associated diseases are characterized by upregulation in expression of ARG1, ARG2, or both, arginase inhibitors are currently being studied as a potential therapeutic approach (1,4).
References
1. S Clemente, G., van Waarde, A., F Antunes, I., Domling, A., & H Elsinga, P. (2020). Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21155291
2. Uniprot (P05089)
3. Kieler, M., Hofmann, M., & Schabbauer, G. (2021). More than just protein building blocks: How amino acids and related metabolic pathways fuel macrophage polarization. The FEBS Journal. Advance online publication. https://doi.org/10.1111/febs.15715
4. Shosha, E., Fouda, A. Y., Narayanan, S. P., Caldwell, R. W., & Caldwell, R. B. (2020). Is the Arginase Pathway a Novel Therapeutic Avenue for Diabetic Retinopathy?. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9020425
5. Correale J. (2021). Immunosuppressive Amino-Acid Catabolizing Enzymes in Multiple Sclerosis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.600428
6. Morales, J. A., & Sticco, K. L. (2020). Arginase Deficiency. In StatPearls. StatPearls Publishing.
Long Name
Liver-Type Arginase
Alternate Names
AI, ARG1, Arginase-1, Liver Arginase, PGIF, Type I Arginase
Gene Symbol
ARG1
UniProt
Additional Arginase 1/ARG1 Products
Product Documents for Arginase 1/ARG1/liver Arginase Antibody
Product Specific Notices for Arginase 1/ARG1/liver Arginase Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...